格隆汇8月27日丨贵州三力(603439.SH)发布2025年半年度报告，报告期实现营业收入7.02亿元，同比下 降23.73%；归属上市公司股东的净利润8306.1万元，同比下降29.04%；扣除非经常性损益后的归属于上 市公司股东的净利润7098.21万元，同比下降37.02%；基本每股收益0.20元。 ...

Group 1 - The board of directors of Guizhou Sanli Pharmaceutical Co., Ltd. held its 15th meeting of the 4th session, which was conducted both in person and via communication voting [1][2] - All 9 directors attended the meeting, and the meeting was presided over by Chairman Zhang Hai, confirming compliance with legal and regulatory requirements [1] - The board approved the company's 2025 semi-annual report and summary, which will be disclosed on the Shanghai Stock Exchange website and other designated media [1][2] Group 2 - The voting results for the approved proposal were 9 votes in favor, with no abstentions, oppositions, or avoidance [2] - The proposal had previously been reviewed and approved by the company's audit committee [2]

Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. reported a decline in revenue and profit for the first half of 2025, attributed to decreased product sales and increased operational costs due to channel expansion efforts [2][13][14]. Company Overview and Financial Indicators - The company’s main business includes the research, production, and sales of pharmaceuticals, with key products such as the Kaihoujian spray [7][21]. - Major financial data for the first half of 2025 includes: - Revenue: CNY 701.83 million, down 23.73% from CNY 920.23 million in the same period last year [2]. - Total profit: CNY 93.91 million, down 32.62% from CNY 139.38 million [2]. - Net profit attributable to shareholders: CNY 83.06 million, down 29.04% from CNY 117.06 million [2]. - Basic earnings per share: CNY 0.20, down 31.03% from CNY 0.29 [2]. Industry Overview - The pharmaceutical manufacturing industry in China experienced a slight decline in revenue and profit, with a 1.2% decrease in revenue and a 2.8% decrease in total profit for large-scale enterprises [13]. - The industry is undergoing transformation driven by policy reforms, demographic changes, and innovation [13][18]. - The aging population is expected to increase demand for chronic disease treatment and health management, with projections indicating a rise in the population aged 60 and above from 320 million to 390 million between 2025 and 2030 [13]. Business Model and Sales Strategy - The company employs a dual-channel sales strategy, focusing on both prescription and OTC (over-the-counter) markets, with a significant emphasis on academic promotion for prescription sales [12][21]. - The company has expanded its OTC channel network, establishing 13 provincial branches and a professional marketing team of over 1,700 members [13][14]. Challenges and Strategic Responses - The company faces challenges due to reduced demand for respiratory-related products and increased operational costs from channel expansion [13][14]. - To address these challenges, the company is implementing cost control measures and refining its marketing strategies to enhance efficiency and profitability [14][18]. Investment and Growth Initiatives - The company has made strategic investments in subsidiaries to enhance control over its supply chain and improve product offerings [15][21]. - A biopharmaceutical fund has been established to focus on innovative drug development, with several projects in clinical trial phases [17]. Commitment to Shareholder Returns - The company emphasizes shareholder returns through cash dividends and share buybacks, with a commitment to distribute at least 50% of its distributable profits as cash dividends annually [17][18].

贵州三力制药股份有限公司2025 年半年度报告摘要 公司代码：603439 公司简称：贵州三力 贵州三力制药股份有限公司 贵州三力制药股份有限公司2025 年半年度报告摘要 第一节 重要提示 展规划，投资者应当到 http://www.sse.com.cn/网站仔细阅读半年度报告全文。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 第二节 公司基本情况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股 票简称 A股 上海证券交易所 贵州三力 603439 不适用 联系人和联系方式 董事会秘书 证券事务代表 姓名 张千帆 鞠灵珂 电话 0851-38113395 0851-38113395 办公地址 贵州省安顺市平坝区夏云工业园区 贵州省安顺市平坝区夏云工业 园区 电子信箱 zhangqf@gz-sanli.com zhangqf@gz-sanli.com 单位：元 币种：人民币 本报告期末比上 本报告期末 上年度末 年度末增减(%) 总资产 2,932,835,729.88 3,192,107,890.63 -8.12 归属于上市公司股东的净资产 1,47 ...

Group 1 - The meeting of the fourth supervisory board of Guizhou Sanli Pharmaceutical Co., Ltd. was held in the company meeting room with all three supervisors present, ensuring the legality and validity of the resolutions made [1][2] - The supervisory board approved the company's 2025 semi-annual report and summary, which will be disclosed on the Shanghai Stock Exchange website and other designated media [1][2]

2025 年 08 月 27 日，贵州三力制药股份有限公司（以下简称"贵州三力"、"公 司"）第四届监事会第十四次会议在公司会议室以现场表决方式召开。本次会议 的会议通知和材料于 2025 年 08 月 20 日以书面及通讯等方式送达所有参会人员。 本次会议应到监事 3 人，实到监事 3 人。本次会议由监事会主席龙静女士召集和 主持，本次会议无列席人员。会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的有关规定，会议决议合法有效。 二、监事会会议审议情况 （一）审议通过《公司 2025 年半年度报告及摘要》 证券代码：603439 证券简称： 贵州三力 公告编号：2025-049 贵州三力制药股份有限公司 第四届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 表决情况：3 票同意；0 票回避；0 票反对；0 票弃权。表决结果：通过。 特此公告。 贵州三力制药股份有限公司监事会 2025 年 08 月 28 日 1 具体内容详见公司同日于上海证券交易所网 ...

二、董事会会议审议情况 会议以记名投票表决方式，审议通过了如下议案： （一）审议通过《公司 2025 年半年度报告及摘要》 证券代码：603439 证券简称：贵州三力 公告编号：2025-048 贵州三力制药股份有限公司 第四届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 2025 年 08 月 27 日，贵州三力制药股份有限公司（以下简称"贵州三力"、"公 司"）第四届董事会第十五次会议在公司会议室以现场和通讯表决方式召开。本 次会议的会议通知和材料于 2025 年 08 月 15 日以书面及通讯等方式送达所有参 会人员。本次会议应到董事 9 人，实到董事 9 人。本次会议由董事长张海先生召 集和主持，本次会议无列席人员。会议的召开符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的有关规定，会议决议合法有效。 特此公告。 贵州三力制药股份有限公司董事会 2025 年 08 月 28 日 1 具体内容详见公司同日于上海证券交易所网站（www.sse.com.cn ...

贵州三力制药股份有限公司2025 年半年度报告 公司代码：603439 公司简称：贵州三力 贵州三力制药股份有限公司 2025 年半年度报告 1 / 161 贵州三力制药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张海、主管会计工作负责人郭珂及会计机构负责人（会计主管人员）郭珂声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的重大风险。公司在本报告"第三节管理 层讨论与分析"中"五、其他披露事项"之"（一）可能面对的风险"章节部分，详细阐述了公 司在未来经营发展中可能面临的各种风险及应对措施，敬请广大投资者认真阅读相关 ...

Core Viewpoint - Guizhou Sanli reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 702 million yuan, representing a year-on-year decrease of 23.73% [1] - Net profit for the same period was 83.061 million yuan, down 29.04% year-on-year [1] - Basic earnings per share were 0.20 yuan, reflecting a decrease of 31.03% compared to the previous year [1]

格隆汇8月15日丨贵州三力(603439.SH)在互动平台表示，公司目前无收购脑机接口相关公司的计划。 ...